- Genetic Analysis of Type 1 Diabetes: Embryonic Stem Cells as New Tools to Unlock Biological Mechanisms in Type 1 Diabetes
- Pathogenic Mechanisms in Type 1 Diabetes: The Islet is Both Target and Driver of Disease
- Comparative Genetics: Synergizing Human and NOD Mouse Studies for Identifying Genetic Causation of Type 1 Diabetes
- Protein Tyrosine Phosphatases and Type 1 Diabetes: Genetic and Functional Implications of PTPN2 and PTPN22
- From Markers to Molecular Mechanisms: Type 1 Diabetes in the Post-GWAS Era
- Novel Biomarkers in Type 1 Diabetes
- Metabolomics in the Studies of Islet Autoimmunity and Type 1 Diabetes
- Gut Microbiota and Type 1 Diabetes
- Virus Infections as Potential Targets of Preventive Treatments for Type 1 Diabetes
- Helminth Infection and Type 1 Diabetes
- Type 1 Diabetes Therapy Beyond T Cell Targeting: Monocytes, B Cells, and Innate Lymphocytes
- Targeted Antigen Delivery to DEC-205+ Dendritic Cells for Tolerogenic Vaccination
- Tolerance Strategies Employing Antigen-Coupled Apoptotic Cells and Carboxylated PLG Nanoparticles for the Treatment of Type 1 Diabetes
- Clinical Potential of Antigen-Specific Therapies in Type 1 Diabetes
- Interleukin-1 Antagonists and Other Cytokine Blockade Strategies for Type 1 Diabetes
- In vivo Delivery of Nucleic Acid-Formulated Microparticles as a Potential Tolerogenic Vaccine for Type 1 Diabetes
- Immune-Directed Therapy for Type 1 Diabetes at the Clinical Level: The Immune Tolerance Network (ITN) Experience
- CD3 Monoclonal Antibodies: A First Step Towards Operational Immune Tolerance in the Clinic
- Islet Transplantation in Type 1 Diabetes: Ongoing Challenges, Refined Procedures, and Long-Term Outcome
- Islet Neogenesis: A Possible Pathway for Beta-Cell Replenishment
